Data from Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Abstract

<div>Abstract<p>Liver metastasis is one of the most important prognostic factors in lung cancer patients. However, current therapies are not sufficient. RNA interference provides us a powerful and promising approach for treating human diseases including cancers. Herein, we investigated the <i>in vitro</i> effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the <i>in vivo</i> usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer. PLK-1 was overexpressed in cell lines and in cancerous tissues from lung cancer patients. PLK-1 siRNA treatment inhibited growth and induced apoptosis in a concentration-dependent manner. To verify <i>in vivo</i> efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted luciferase-labeled A549<sup>LUC</sup> cells by detecting reduced bioluminescence after an i.v. injection of luciferase GL3 siRNA/atelocollagen. PLK-1 siRNA/atelocollagen was also successfully transfected into cells and inhibited the progression of metastases. This study shows the efficacy of i.v. administration of PLK-1 siRNA/atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer. [Mol Cancer Ther 2008;7(9):2904–12]</p></div>